Publications by authors named "S Sardesai"
Background: Dietary patterns promoting chronic inflammation, including the empirical dietary inflammatory pattern (EDIP), have been associated with certain cancers. Investigating whether this dietary pattern is associated with breast cancer-where the role of inflammation is less well-defined-could provide valuable insights and potentially improve strategies for preventing this cancer.
Methods: We prospectively followed 76,386 women from Nurses' Health Study (NHS, 1984-2018) and 92,886 women from Nurses' Health Study II (NHSII, 1991-2019).
Article Synopsis
- Chemotherapy often leads to severe gastrointestinal issues in patients, with existing treatments failing to provide adequate relief.
- Recent findings suggest that the gut microbiome influences the severity of these symptoms, prompting research into identifying pre-chemotherapy microbiome markers.
- In a study of 59 breast cancer patients, lower microbiome diversity and specific microbial abundance predicted worse gastrointestinal symptoms during chemotherapy, indicating potential for personalized preventative strategies based on microbiome health before treatment.
Purpose: Routine imaging of soft tissue infection is not recommended and represents a potential area of CT overuse. The utility of CT in patients with superficial soft tissue infection of the extremities is unknown. The purpose of this study is to evaluate the utilization and clinical impact of CT ordered in the setting of extremity cellulitis.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the relationship between the empirical dietary inflammation pattern score (EDIP) and mammographic density (MD), as well as the influence of body mass index (BMI) in this relationship.
- It included 4,145 participants from the Nurses' Health Study, assessing diet through questionnaires and measuring various MD parameters.
- Results showed an overall negative correlation between EDIP and percent MD, with a significant portion of this relationship explained by differences in BMI, while no strong links were found between EDIP and dense area or grayscale variation.
There is limited data regarding the added benefit of adjuvant systemic therapy in the management of small, node-negative, HER2+ breast cancer. In a multi-institutional retrospective analysis using the American Society of Clinical Oncology CancerLinQ database, we compared survival outcomes among T1a-c N0 HER2+ patients diagnosed between 2010 to 2021 who received locoregional therapy alone or in combination with adjuvant trastuzumab (+/- chemotherapy). Primary outcomes were invasive disease-free survival (iDFS) and overall survival (OS).
View Article and Find Full Text PDF